<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03802162</url>
  </required_header>
  <id_info>
    <org_study_id>179BE18029</org_study_id>
    <nct_id>NCT03802162</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355</brief_title>
  <official_title>An Open-label, Randomized, Multiple-dosing Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 With D797 and D324 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of
      CKD-355.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, multiple-dosing parallel study to evaluate the pharmacokinetics,
      safety and tolerability of CKD-355 with D797 and D324 in healthy subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2019</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">May 10, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of D324</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>Max Concentration of D324</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of D324</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>Area under the curve of D324</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of D797</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>Max Concentration of D797</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of D797</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>Area under the curve of D797</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmin of D324</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>Min Concentration of D324</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of D797</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>Min Concentration of D797</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of D324</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>Time of Max concentration of D324</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of D797</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>Time of Max concentration of D797</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½ of D324</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>Half-life time of D324</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½ of D797</measure>
    <time_frame>0(predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours</time_frame>
    <description>Half-life time of D797</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Alzheimer's Disease (AD)</condition>
  <arm_group>
    <arm_group_label>CKD-355A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-355B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D797, D324</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-355A (D797/Memantine HCl 20mg)</intervention_name>
    <description>once a day</description>
    <arm_group_label>CKD-355A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-355B (D797/Memantine HCl 20mg)</intervention_name>
    <description>once a day</description>
    <arm_group_label>CKD-355B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D797</intervention_name>
    <description>once a day</description>
    <arm_group_label>D797, D324</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D324 (Memantine HCl 10mg)</intervention_name>
    <description>twice a day</description>
    <arm_group_label>D797, D324</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult older than 19 years and less than 55 years at the time of screening

          2. BMI 18.5~29.9 kg/m2 and body weight more than 50kg

          3. Subjects who have consented to the use of appropriate double- pregnancy contraceptive
             methods up to two months after the last investigational product and not to provide
             sperm for men

          4. Subjects who sign on an informed consent form willingly

        Exclusion Criteria:

          1. Subjects who have a clinically significant disease such as respiratory, hepatic,
             kidneys, blood, gastrointestinal, endocrine, immune system, skin, nercous and mental
             disease.

          2. Subjects who have acute disease within 28 days prior to the first administration

          3. Subjects who have history that may affect the ADME

          4. Subjects who have clinically significant chronic disease

          5. Women who are nursing, pregnant or positive on pregnancy test

          6. Subjects who have clinically significant allergic diseases

          7. Subjects with genetic problems such as galactose intolerance, Lapp lactase deficiency
             or glucose-galactose malabsorption

          8. Subjects who are known to be hypersensitive to the drug or its components

          9. Subjects who have been found to be positive in serological tests (HBs antigen, HCV
             antibody and HIV antibody)

         10. Subjects with creatinine clearance &lt;60 ml / min

         11. Subjects whose AST or ALT levels exceeded 2.5 times of upper limit of normal range

         12. Subjects who taked ETC(Ethical Drug), oriental medicine within 2 weeks and
             OTC(Over-the-counter Drug), vitamin within 1 week prior to the first administration

         13. Subjects who can not eat standard meals provided by the institution.

         14. Subjects who donated whole blood within 60 days, donated the components within 20 days
             or received blood within 30 days

         15. Subjects who taked medication for the induction and inhibition of metabolizing enzymes
             such as barbiturate drugs within 30 days before the first administration

         16. Subjects who have had abnormal diets that can affect the ADME of the drug within 30
             days before the first administration (eg, ingestion of grapefruit juice&gt;1 L / day)

         17. Subjects who participate in the other clinical trial within 90 days prior to the first
             administration

         18. Subjects who have a history of regular alcohol(alcohol&gt;210g/week) or
             caffeine(caffeine&gt;5 cups/day)

         19. Subjects who smokes more than 10 cigarettes per day within 3 months or cannot
             discontinue smoking during the clinical trial

         20. Subjects who is determined unsuitable to participate in this clinical trial by the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 10, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>CKD-355</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

